Banner

Serum retinol‐binding protein: a novel biomarker for recalcitrant cutaneous warts

International Journal of Dermatology • 2019
Back
Publication Information
Authors Ola El-Shimi, Amany Mostafa, Fatma El-Esawy
Keywords Not Available
Journal International Journal of Dermatology
Publisher Wiley
Volume Not Available
Issue Not Available
Pages Not Available
publication.type International
Paper Link Not Available
Supplementary Materials Not Available
Abstract
Background: Cutaneous viral warts are benign epidermal proliferations caused by human papillomaviruses (HPVs). Despite treatment, a significant proportion of warts fail to resolve, becoming recalcitrant. Vitamin A (retinol) may disrupt the interplay of HPV replication and epithelial cell differentiation, allowing normal tissue to replace warts. Circulating retinol‐binding protein (RBP) concentrations highly correlate with retinol levels. Aim: We aimed at evaluation of serum RBP level in patients with recalcitrant cutaneous warts in order to assess its correlation with disease pathogenesis. Methods: Serum RBP level was measured by an ELISA technique in 50 patients with recalcitrant cutaneous warts and 30 apparently healthy controls. Results: Serum RBP level was significantly lower in patients with recalcitrant warts than the control group (P < 0.001). However, it did not differ regarding different clinical parameters in studied patients (P > 0.05 each). RBP is a reliable biomarker for significant early detection and discrimination between patients and healthy controls (P < 0.001) at a cutoff value ≤1034.6 μg/ml, with sensitivity and specificity (100% each). Conclusion: Our results revealed that low serum RBP as a relatively cheap biomarker with high specificity and sensitivity is a reliable indicator of vitamin A (retinol) deficiency that may play a role in the pathogenesis of recalcitrant cutaneous warts among our studied patients.